Join
Live feed
·
PRReleasevia Quantisnow
Athira Pharma Inc. logo

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

ByQuantisnow·Wall Street's wire, on your screen.
ATHA· Athira Pharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ATHA (Athira Pharma Inc.) and more on Quantisnow.